You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAID
DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDS
Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: N
DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Xona Microfluidics, Inc. Topic: NIMH
DESCRIPTION (provided by applicant): Neuron-cell culture is widely used for studies in basic research, drug discovery, and toxicity testing. Traditional random cultures allow limited access to subcellular compartments (axons, dendrites, synapses) due to extensive and haphazard growth of neurons. Our long-term goal is to provide robust, user-friendly, and cost effective culture platforms that can o ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: MUVE, INC. Topic: NIDDK
DESCRIPTION (provided by applicant): It is uniformly recognized that sedentariness - the sitting disease - is bad for the health of the nation. The solution to reversing sedentariness involves devising and disseminating real-world solutions to promote day-long physical activity and help people who want to, to lose weight and improve their blood glucose, lipids and blood pressure. The Gruve is ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health